Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atosiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 5/20 | 0.67 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.65 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atosiban SCHEMBL29522709 | 0.97 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL1648581 | 0.97 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL19712221 | 0.97 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL34316 | 0.97 | OXTR (0.71) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL4410202 | 0.96 | OXTR (0.69) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL3138542 | 0.95 | OXTR (0.69) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL21255736 | 0.92 | OXTR (0.72) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL26813594 | 0.87 | OXTR (0.58) | OXTRAVPR1AAVPR1BAVPR2 | |
| Atosiban SCHEMBL13723569 | 0.86 | OXTR (0.56) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15511860 | 0.86 | OXTR (0.81) | OXTRAVPR1AAVPR1BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103980350-A | Solid-phase cyclization synthesis method of Atosiban | HANGZHOU SINOPEP PHARMACEUTICA | 2014-08-13 | — | — | CN | disclosed |
| EP-2119724-A1 | Solid-phase process foor the preparation of goserelin | Novetide Ltd. (IL) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119725-A1 | Methods for the production of leuprolide | Novetide Ltd. (IL) | 2009-11-18 | — | — | EP | disclosed |
| EP-1773870-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | Novetide Ltd. (IL) | 2007-04-18 | — | — | EP | disclosed |
| US-20060276626-A1 | Methods for the production of peptide derivatives | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006119388-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | NOVETIDE, LTD. (IL) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276626-A1 | Methods for the production of peptide derivatives | VIP, IAPP, PTMS | OXTR 1488/4885AVPR1A 349/4885AVPR1B 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.